Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathy - Covert encephalopathy and Rifaximin

Wakayama Medical University0 个研究点目标入组 40 人开始时间: 2021年7月1日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1. Patients who are not in a clear state of consciousness 2. Patients with psychiatric disorders (depression, masked depression, schizophrenia, dementia, etc.) 3. Patients with malignant tumors including hepatocellular carcinoma 4. Patients with any of the following complications 1) Ascites requiring periodic drainage 2) Bleeding due to rupture of esophageal or gastric varices 3) Spontaneous bacterial peritonitis 4) Severe electrolyte abnormalities that may affect neuropsychiatric function 5. Patients with a history of hypersensitivity to rifaximin 6. Patients with the following serious complications 1) Patients with severe renal dysfunction or end-stage renal failure on dialysis 2) Patients with poorly controlled myocardial infarction, heart failure, angina pectoris, arrhythmia, etc. 7. New administration or change in dosage of synthetic disaccharides, carnitine, zinc, or laxatives between 4 weeks before and 12 weeks after administration of rifaximin 8. Pregnant women, lactating women, and patients who may or intend to become pregnant 9. Patients who have difficulty in oral intake 10. Other patients who are deemed by the physician to be inappropriate for the safe conduct of this study

发起方